113 related articles for article (PubMed ID: 25374008)
1. Oral vaccination of mice with Tremella fuciformis yeast-like conidium cells expressing HBsAg.
Shin DI; Song KS; Park HS
Biotechnol Lett; 2015 Mar; 37(3):539-44. PubMed ID: 25374008
[TBL] [Abstract][Full Text] [Related]
2. Comparison of a bacteriophage-delivered DNA vaccine and a commercially available recombinant protein vaccine against hepatitis B.
Clark JR; Bartley K; Jepson CD; Craik V; March JB
FEMS Immunol Med Microbiol; 2011 Mar; 61(2):197-204. PubMed ID: 21204995
[TBL] [Abstract][Full Text] [Related]
3. Cationic transfersomes based topical genetic vaccine against hepatitis B.
Mahor S; Rawat A; Dubey PK; Gupta PN; Khatri K; Goyal AK; Vyas SP
Int J Pharm; 2007 Aug; 340(1-2):13-9. PubMed ID: 17446015
[TBL] [Abstract][Full Text] [Related]
4. Antibody responses in mice stimulated by various doses of the potato-derived major surface antigen of hepatitis B virus.
Youm JW; Won YS; Jeon JH; Moon KB; Kim HC; Shin KS; Joung H; Kim HS
Clin Vaccine Immunol; 2010 Dec; 17(12):2029-32. PubMed ID: 20943879
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis B virus surface antigen as delivery vector can enhance Chlamydia trachomatis MOMP multi-epitope immune response in mice.
Zhu S; Feng Y; Rao P; Xue X; Chen S; Li W; Zhu G; Zhang L
Appl Microbiol Biotechnol; 2014 May; 98(9):4107-17. PubMed ID: 24458565
[TBL] [Abstract][Full Text] [Related]
6. [Suppression of the antigen-specific T cell immune response by co-immunization with the HBV DNA vaccine and recombinant HBsAg].
Du X; Wang J; Kang Y; Xiao W; Zhao G; Wang B
Wei Sheng Wu Xue Bao; 2009 Jul; 49(7):938-42. PubMed ID: 19873759
[TBL] [Abstract][Full Text] [Related]
7. Oral immunization of animals with transgenic cherry tomatillo expressing HBsAg.
Gao Y; Ma Y; Li M; Cheng T; Li SW; Zhang J; Xia NS
World J Gastroenterol; 2003 May; 9(5):996-1002. PubMed ID: 12717845
[TBL] [Abstract][Full Text] [Related]
8. Recombinant Semliki Forest virus vectors encoding hepatitis B virus small surface and pre-S1 antigens induce broadly reactive neutralizing antibodies.
Niedre-Otomere B; Bogdanova A; Skrastina D; Zajakina A; Bruvere R; Ose V; Gerlich WH; Garoff H; Pumpens P; Glebe D; Kozlovska T
J Viral Hepat; 2012 Sep; 19(9):664-73. PubMed ID: 22863271
[TBL] [Abstract][Full Text] [Related]
9. Lentivector expressing HBsAg and immunoglobulin Fc fusion antigen induces potent immune responses and results in seroconversion in HBsAg transgenic mice.
Hong Y; Peng Y; Mi M; Xiao H; Munn DH; Wang GQ; He Y
Vaccine; 2011 May; 29(22):3909-16. PubMed ID: 21421003
[TBL] [Abstract][Full Text] [Related]
10. [Construction of recombinant adeno-associated virus carrying hepatitis B surface antigen gene and preliminary study of the gene expression and function].
Hu GF; Wu XB; Yu SY; Dong XY; Chen Q; Hou YD
Di Yi Jun Yi Da Xue Xue Bao; 2003 Jun; 23(6):553-6. PubMed ID: 12810373
[TBL] [Abstract][Full Text] [Related]
11. Longitudinal determination of hepatitis B surface antigen-specific B lymphocyte frequency in healthy high responder adults after booster vaccination.
Sam MR; Shokrgozar MA; Shokri F
Intervirology; 2008; 51(2):87-95. PubMed ID: 18477849
[TBL] [Abstract][Full Text] [Related]
12. Oral administration of low doses of plant-based HBsAg induced antigen-specific IgAs and IgGs in mice, without increasing levels of regulatory T cells.
Kostrzak A; Cervantes Gonzalez M; Guetard D; Nagaraju DB; Wain-Hobson S; Tepfer D; Pniewski T; Sala M
Vaccine; 2009 Jul; 27(35):4798-807. PubMed ID: 19539581
[TBL] [Abstract][Full Text] [Related]
13. Optimization of immune responses induced by therapeutic vaccination with cross-reactive antigens in a humanized hepatitis B surface antigen transgenic mouse model.
Bourgine M; Dion S; Godon O; Guillen G; Michel ML; Aguilar JC
Virology; 2012 Aug; 430(1):10-9. PubMed ID: 22591777
[TBL] [Abstract][Full Text] [Related]
14. M-cell targeted delivery of recombinant hepatitis B surface antigen using cholera toxin B subunit conjugated bilosomes.
Shukla A; Katare OP; Singh B; Vyas SP
Int J Pharm; 2010 Jan; 385(1-2):47-52. PubMed ID: 19835938
[TBL] [Abstract][Full Text] [Related]
15. Humoral response and genetic stability of recombinant BCG expressing hepatitis B surface antigens.
Rezende CA; De Moraes MT; De Souza Matos DC; McIntoch D; Armoa GR
J Virol Methods; 2005 Apr; 125(1):1-9. PubMed ID: 15737410
[TBL] [Abstract][Full Text] [Related]
16. Novel nanocarrier for oral Hepatitis B vaccine.
Dinda AK; Bhat M; Srivastava S; Kottarath SK; Prashant CK
Vaccine; 2016 Jun; 34(27):3076-3081. PubMed ID: 27156634
[TBL] [Abstract][Full Text] [Related]
17. Oral delivery of wafers made from HBsAg-expressing maize germ induces long-term immunological systemic and mucosal responses.
Hayden CA; Fischer ME; Andrews BL; Chilton HC; Turner DD; Walker JH; Tizard IR; Howard JA
Vaccine; 2015 Jun; 33(25):2881-6. PubMed ID: 25944300
[TBL] [Abstract][Full Text] [Related]
18. Immune responses to hepatitis B virus surface and core antigens in mice, monkeys, and pigs after Accell particle-mediated DNA immunization.
Fuller JT; Fuller DH; McCabe D; Haynes JR; Widera G
Ann N Y Acad Sci; 1995 Nov; 772():282-4. PubMed ID: 8546409
[No Abstract] [Full Text] [Related]
19. Novel immunogenicity of Oka varicella vaccine vector expressing hepatitis B surface antigen.
Kamiyama T; Sato H; Takahara T; Kageyama S; Shiraki K
J Infect Dis; 2000 Mar; 181(3):1158-61. PubMed ID: 10720546
[TBL] [Abstract][Full Text] [Related]
20. [The prospects for using the genetically engineered surface antigen of the hepatitis B virus (HBsAg) expressed by recombinant poxvirus strains as the basis for vaccines against hepatitis B].
Zheleznova NV; Mukomolov SL; Zhebrun AB; Noskov FS; Malkova II; Shargorodskaia EP; Al'tshteĭn AD; Pliutnikova VA; Lavrent'eva IN; Ptichnikova NN
Zh Mikrobiol Epidemiol Immunobiol; 1996; (5):49-53. PubMed ID: 9082729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
